

3-10-05

Express Mail No. ED 311 827 541 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Brines et al.

Confirmation No.:

7980

Serial No.:

10/676,694

Art Unit:

1647

Filed:

September 30, 2003

Examiner:

To Be Assigned

For:

TISSUE PROTECTIVE CYTOKINE

Attorney Docket No:

10165-027-999

RECEPTOR COMPLEX AND ASSAYS FOR

IDENTIFYING TISSUE PROTECTIVE

**COMPOUNDS** 

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to the references A01-A09, B01-B02 and C01-C49 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references B01-B02 and C01-C49 are enclosed herewith.

Pursuant to M.P.E.P. Section No. 609 III (A)(2), copies of references A01 to A08 are not submitted herewith.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449, and that they be made of record in the file history of the above-identified application.

KECEINED

Pursuant to 37 C.F.R. §1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date:

March 9, 2005

Jama A. love

30,742

Laura A. Coruzz

(Reg. No.)

By:

Joseph P. Cahill

51,523 (Reg. No.)

**JONES DAY** 

222 East 41st Street

New York, New York 10017

(212) 790-9090

**Enclosures** 

MAR 6 9 2005 E

IST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO. 10165-027-999 10/676,694					
APPLICANT Brines et al.					
FILING DATE September 30, 2003	GROUP 1647				

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	2004/0214236	10/28/04	Brines et al.			
· · · · · · · ·	A02	2004/0122216	6/24/04	Nielsen et al.			,
	A03	2003/0134798	7/17/03	Brines et al.			
	A04	2003/0104988	6/5/03	Brines et al.			
	A05	2003/0072737	4/17/03	Brines et al.			
	A06	2002/0031806	3/14/02	Lee			
•	A07	6,531,121	3/11/03	Brines et al.			
	A08	5,763,198	6/9/98	Hirth et al.			
	A09	5,292,654	3/8/94	Yoshimura et al.			

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION.
						YES	NO
В0	WO 04/096148	11/11/04	PCT				
B0:	WO 02/053580	7/11/02	PCT				
	_						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
C01	Barber et al.,1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," Mol. Cell. Biol. 14(10):6506-6514				
C02	Barbone et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," J. Biol. Chem. 272(8):4985-4992				
C03	Bazan, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," Biochem. Biophys. Res. Commun. 164(2):788-795				
C04	Benit et al., 1993, "The WS motif common to v-mpl and members of the cytokine receptor superfamily is dispensable for myeloproliferative leukemia virus pathogenicity," Oncogene 8(3):787-790				
C05	Bonsi et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," Br. J. Haematol. 98(3):549-559				
C06	Boudot et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," J. Biol. Chem. 274(48):33966-33972				
C07	Brizzi et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9(4):274-300				
C08	Caravella et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24(3):394-401				
C09	D'Andrea et al., 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hernatol. 28(3):231-243				
C10	D'Andrea et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960				
C11	D'Andrea and Zon, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687				

		Sheet 2 of 3
	C12	Frank, 2002, "Receptor dimerization in GH and erythropoietin actionit takes two to tango, but how?" Endocrinology 143(1):2-10
	C13	Fung et al., 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," Semin. Immunol. 2(2):119-128
	C14	Grotzinger, 2002, "Molecular mechanisms of cytokine receptor activation," Biochim. Biophys. Acta. 1592(3):215-223
	C15	Hanazono et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the b chain of the GM-CSF receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066
<del>-</del>	C16	Harris et al. 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in Escherichia coli," J. Biol. Chem. 267(21):15205-15209
	C17	Hassan et al., 1995, "Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res.
	C18	Inada et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357
	C19	Itoh et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247(4940):324-327
	C20	Jenkins et al., 1999, "A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation," J. Biol. Chem. 274(13):8669-8677
	C21	Jones et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35
<u>-</u>	C22	Jubinsky et al., 1997, "The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," Blood 90(5):1867-1873
•	C23	Jubinsky et al., 1996, "The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression," Mol. Med. 2(6):766-773
•	C24	Kirito et al., 2002, "Identification of the human erythropoietin receptor region required for Stat 1 and Stat3 activation," Blood 99(1):102-110
	C25	Lai et al., 1996, "The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes." Proc. Natl. Acad. Sci. USA 93(1):231-235
	C26	Lewis et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro," Exp. Hematol. 32(1):36-44
	C27	Lewis et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93(1):75-80
-	C28	Liu et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc," Mol. Cell. Biol. 14(10):6926-6935
	C29	Livnah et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283(5404):987-990
	C30	McClure et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243
	C31	Means et al., 1996, "Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor," Exp. Hematol. 24(2):204-208
	C32	Murakami et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353
	C33	Murray, 1996, Harpers Biochemistry 24th ed. pp.524-526, Appilion & Lange, Ltd.
	C34	Naranda et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302
	C35	Nathan, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 Suppl 1:27-33
	C36	Noguchi et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556
	C37	Penny and Forget, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980
	C38	Remy et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283(5404):990-993
	C39	Scott et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590
	C40	Shikama et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464
	C41	Tojo et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448
	C42	Williamson et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344
	C43	Winkelmann et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p," Blood 76(1):24-30
	C44	Yamamura et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915
	1	NYID: 1563881 1

Sheet 3 of 3

	C45	Yet et al, 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719
	C46	Yoshimura et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063
	C47	Yoshimura et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction," Oncologist 1(5):337-339
•.	C48	Yoshimura et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826
	C49	Zhu et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7

1	
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.